ABX-900

N/A

Report date: 2025/04/21 17:03:48

Base Information

Drug NameABX-900
Drug Alias Namebispecific centyrins (Janssen/Fusion Pharmaceuticals)bispecific centyrins (J&J)bispecific centyrins (Janssen)anti EGFR/c-Met bispecific centyrins (Aro Biotherapeutics/Fusion Pharmaceuticals)ABX-900 +[6] 
ClassificationBiologics
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsHepatocyte growth factor receptor inhibitors
TargetsEpidermal growth factor receptor erbB1Hepatocyte growth factor receptor
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsHead and Neck Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesJanssen Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAro Biotherapeutics Co
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsHead and Neck Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A